Jurata Thin Film is a technology company.
Jurata Thin Film has raised $5.0M across 1 funding round.
Jurata Thin Film has raised $5.0M in total across 1 funding round.
Jurata Thin Film has raised $5.0M in total across 1 funding round.
Jurata Thin Film's investors include Golden Seeds.
Jurata Thin Film is a biotechnology company developing thermostable thin film formulations for vaccines, biologics, and advanced therapeutics, enabling room-temperature storage for up to three years and needle-free administration without cold chain requirements.[1][2][4][5] It serves the healthcare and biotech industries by simplifying manufacturing, distribution, storage, and delivery, particularly for hard-to-reach areas, with applications in human and animal health.[1][3][6] Founded in 2019 and based in Houston, Texas (with operations in Chapel Hill, NC), the company has raised $4.87M in grant funding and remains in the early-stage "Grant | Alive" phase, demonstrating growth through partnerships like Johnson & Johnson Innovation.[1][3][7]
Jurata's journey began in 2014 amid the Ebola outbreak in West Africa, where founders identified the need for vaccines distributable without refrigeration or needles in remote areas.[4] Incorporated in 2019 in Houston, Texas, the company was co-founded by experienced leaders in drug development, formulation, and manufacturing; key figures include the Co-Founder and Executive Chair, and Co-Founder and Board Member, supported by a leadership team with roles like CEO, CFO, VP of Science & Technology, and advisors from firms like Kensington Street Consulting.[1][2][4] The COVID-19 pandemic in 2020 provided pivotal validation, highlighting cold chain limitations, supply disruptions, and access barriers, which expanded the technology's scope beyond public health emergencies to chronic treatments.[4] Early traction includes grant funding and ecosystem collaborations, such as recognition in J&J's BLUE KNIGHT™ program.[1][7]
Jurata rides the trend toward resilient biotech supply chains, amplified by pandemics like Ebola and COVID-19, which exposed cold chain vulnerabilities wasting doses and excluding remote populations.[1][4] Timing aligns with global demands for equitable vaccine access, supply chain de-risking, and needle-free options amid rising biologics complexity and animal health needs.[2][4][6] Market forces favoring it include regulatory pushes for thermostable tech (e.g., BARDA/J&J initiatives) and a $100B+ biologics market strained by logistics costs.[1][7] By enabling global reach without freezers or needles, Jurata influences the ecosystem, accelerating commercialization, fostering collaborations, and paving the way for first-in-class therapies in underserved regions.[4][5]
Jurata is poised to scale through partnerships and grants, targeting broader adoption in vaccines, therapeutics, and animal health amid ongoing supply chain pressures.[1][4][6] Trends like mRNA/biologic expansion, climate-impacted logistics, and preparedness initiatives (e.g., BLUE KNIGHT™) will propel its platform, potentially unlocking licensing deals or acquisitions by pharma giants.[1][4][7] Its influence may evolve from niche innovator to supply chain standard-setter, fully realizing the 2014 Ebola-inspired vision of barrier-free global medicine delivery.[4]
Jurata Thin Film has raised $5.0M across 1 funding round. Most recently, it raised $5.0M Seed in November 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2022 | $5.0M Seed | Golden Seeds |